In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

In considering the evolution of drug discovery and development in the cardiovascular area, it is important to realize that the term "cardiovascular disease" refers to a number of conditions ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

So, will Merck make its $10 billion target for cardiovascular drugs? No doubt, according to analyst Akash Tewari of Jefferies, who reckons that sotatercept will become a $7.5 billion drug at peak ...

In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug ... year to develop cardiovascular medication ...

There's an arms race in medicine -- scientists design drugs to treat lethal bacterial infections, but bacteria can evolve defenses to those drugs, sending the researchers back to square one.

Two years after she started taking Xanax, Dana Bare began having panic attacks like never before. Her memory started slipping. Her husband had to remind her how to make a sandwich. Bare’s ...